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among patients receiving different HA treatments in a commercially-insured cohort 
of patients with knee OA. Methods: Retrospective analyses using IMS Health’s 
PharMetrics Plus Health Plan Claims Database were conducted by identifying knee 
OA patients with claims indicating initiation of HA treatment at an index date 
during the selection period (2007-2010). Patients were required to be continuously 
enrolled in the health claims database from 12-months pre-index to 36-months 
post. A generalized linear model (GLM) with a gamma distribution and log-link 
function was used to model aggregate patient-based changes in disease-specific 
costs. A Cox proportional hazards model (PHM) was used to model risk of TKR. Both 
multivariate models included covariates such as age, gender, comorbidities, and 
pre-index healthcare costs. Results: 50,389 patients with HA treatment for knee 
OA were identified. 18,217 (36.2%) patients received Supartz/Hyalgan (shared HCPCS 
code), 20,518 (40.7%) Synvisc, 6,263 (12.4%) Euflexxa, and 5,391 (10.7%) Orthovisc. 
Synvisc and Orthovisc patients showed more disease-specific costs compared to 
Supartz/Hyalgan (8.9% (p< 0.0001) and 6.8% (p= 0.0048) increase respectively). This 
implies that if users of Synvisc and Orthovisc with average disease-specific costs 
of $14,959 and $14,224 switch to Supartz/Hyalgan, they can save $1,223 and $906 
over 3 years respectively. Hazard ratios showed a significantly higher risk of TKR 
for patients receiving Synvisc compared to Supartz/Hyalgan (6.9% increase in haz-
ard (p= 0.0009)). Patients treated with Supartz/Hyalgan, Euflexxa and Orthovisc had 
longer delays of TKR. ConClusions: Multivariate statistical modeling showed that 
Supartz/Hyalgan represents a cost-effective alternative for providers. Both HAs 
reduce disease-specific costs and delay TKR when compared to other products.
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objeCtives: Approximately 80% of US hemodialysis patients initiate dialysis with 
a central venous catheter (CVC) despite their high incidence of infections compared 
to other vascular access modalities (USRDS 2011). Early cannulation arteriovenous 
grafts (ecAVGs) can be cannulated within 24 hours of implantation thus minimizing 
the dependency on CVCs compared to non-ecAVGs. We compare CVC sepsis costs for 
patients implanted with ecAVGs to those with non-ecAVGs. Methods: An economic 
model was estimated using the GORE® ACUSEAL Vascular Graft (GAVG) Clinical Study 
(Clinicaltrials.gov NCT01173718), clinical literature, and publicly available cost sources. 
The GAVG study was a prospective, multi-center, single-arm study to establish the 
safety and efficacy of the GAVG for use in hemodialysis access. The study collected 
data on the first three consecutive hemodialysis sessions, which is a surrogate end-
point for time to potential CVC removal. The median days to potential CVC removal 
was 15.5 compared to an average of 34 days for non-ecAVGs from Quinn (2009) and 
Shingarev et al. (2011). CVC sepsis rates of 2.32 per patient-year were obtained from 
the US Renal Data System (2011). The CVC sepsis hospitalization cost was calculated 
as $27,088 (2014 dollars) from HCUP NIS (2010). Results: Assuming 100 patients in 
each group, the ecAVG group was estimated to have 9.9 CVC sepsis episodes com-
pared to 21.6 in the non-ecAVG group, with estimated sepsis hospitalization costs 
of $268,171 versus $585,100, respectively, due to the extended time on the CVC. The 
ecAVG potentially reduces CVC sepsis episodes by 11.7 since it reduces the number 
of catheter-dependent days by 18.5 compared to the non-ecAVG. On a per patient 
basis, the estimated average CVC sepsis costs in the ecAVG group were $2,682/patient 
versus $5,851/patient in the non-ecAVG group, resulting in a cost savings of $3,189/
patient. ConClusions: It is estimated ecAVGs reduce overall CVC sepsis costs com-
pared to non-ecAVGs due to fewer CVC-dependent days.
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objeCtives: Manual suturing is currently used to perform ileocolic anastomosis in 
colorectal surgery. Because of its documented post-surgical complications shown 
in literature (anastomotic leaks and reoperations), alternative techniques such as 
mechanical stapling might yield clinical and economic benefits for hospitals. The 
objective of this study was to estimate the economic impact derived from the use of 
mechanical stapling and handsewn techniques in open ileocolic anastomoses from 
a Mexican public hospital perspective (IMSS). Methods: An Excel-based decision 
tree model was used to compare clinical and economic outcomes of both anasto-
moses techniques. Data for anastomotic leak and reoperation rates for mechanical 
and handsewn suturing were taken from international published literature. Given 
procedure volume variability in comparable hospitals, base-case scenario assumed 
100 annual procedures with each anastomosis technique. Considered complications 
were anastomotic leak (requiring readmission) and reoperation due to fistuliza-
tion and anastomotic stricture. Stapler, cutter and traditional suture utilization 
patterns were based on expert opinions, while their unitary costs were provided 
by internal resources. Inflation-adjusted DRGs from IMSS´s second level hospitals 
were used as hospitalization, readmission and reoperation costs. Results are shown 
in 2015-adjusted USD; considered time horizon was < 1 year, thus no discount rate 
for costs was necessary. Results: Stapled colorectal anastomoses resulted in a 
significant reduction in anastomotic leaks and reoperations compared to handsewn 
technique. Net potential savings due to avoided readmissions and reoperations with 
mechanical stapler accounted for $32,422 and $197,992 respectively; net saving per 
patient was $1,784. ConClusions: The use of stapling devices to perform ileocolic 
anastomosis can yield potential clinical and economic benefits due to the reduction 
of readmission and reoperation rates. Local public healthcare institutions should 
consider the adoption of mechanical stapling techniques in colorectal surgery as it 
appears to be a cost saving alternative.
appropriate care when the blood-based EGFR mutation testing was used as an alter-
native test to tissue-based EGFR mutation testing alone (93% vs 90%, respectively). 
As a result of increased diagnostic yield, there was a 23% decrease in cost per 
NSCLC patient per month compared to tissue-based testing alone ($1,665 vs $1,265). 
Costs per NSCLC patient per month are similar when blood-based testing is used 
in place of CT scan for ongoing monitoring of tumor progression. ConClusions: 
The blood-based cobas® EGFR Mutation Test has advantages for patient outcomes 
when performed as an alternative test to tissue-based testing when tissue sample 
is not available or when used as an ongoing monitoring tool for tumor progres-
sion. By correctly identifying more patients for proper treatment, the blood-based 
test represents a good alternative to tissue-based testing for identification of EGFR 
mutations in locally advanced or metastatic NSCLC patients.
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objeCtives: Advances in molecular diagnostics for the detection of disease can pro-
vide opportunities for healthcare providers to intervene earlier and subsequently, 
improve outcomes. Payers are increasingly focused on assessing the cost and over-
all value of such tools. The kSORT assay is a non-invasive test that can be used 
as a screening tool to detect subclinical rejection (SCR) among kidney transplant 
patients. The current standard of care may consist of routine screening for clini-
cal acute rejection (AR) or the use of invasive surveillance biopsies to detect SCR 
through histologic diagnosis. Preliminary data show that the k-SORT assay performs 
as well as and potentially superior to biopsies for the detection of SCR and prediction 
of AR. The objective of this analysis is to evaluate the potential budget impact of 
the kSORT assay from a commercial payer perspective using a set of conservative 
assumptions. Methods: A 2-year Markov model incorporating SCR, AR, and graft 
failure was developed to evaluate the budget impact from a U.S. commercial payer 
perspective of the k-SORT assay among patients with incident kidney transplants. 
Probabilities for progression were obtained by calibrating the values to correspond 
with reported prevalence rates of SCR and incidence rates of AR from published 
registry data. Costs were obtained through the peer-reviewed literature and sensitiv-
ity analyses were performed. Results: Across a set of conservative assumptions, 
use of the kSORT assay may have a minimal budget impact (< $0.05) PMPM across 
most scenarios. Key value drivers include the frequency of monitoring, costs of 
the assay, and concurrent use of protocol biopsies with the assay. ConClusions: 
The use of k-SORT to detect SCR is likely to produce a minimal budget impact for 
commercial payers. Additional studies demonstrating the clinical performance of 
the assay compared to biopsies can help to provide further insight into the clinical 
and economic benefits.
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objeCtives: Hypoglycemic events (HEs) are important acute complications in 
patients with diabetes mellitus, especially insulin-treated. Severe HEs (sHEs) cause 
high treatment costs and have a major impact on patients’ quality of life. A newly 
available, innovative blood glucose measurement device (IBGMD), using a technology 
identifying patterns of low blood glucose and alerting the patient about a potential 
sHE (“pattern alert technology”, PAT), is studied to determine (i) the number of avoid-
able sHEs through deployment of IBGMD using PAT, compared to a conventional 
blood glucose measurement device (CBGMD), (ii) the IBGMD net cost, and (iii) its 
impact on overall management costs. Methods: Values attached to epidemiologic, 
cost and behavioral input variables were taken from scientific literature and authori-
tative sources. A decision-analytic, one-year model comparing direct costs (payer 
perspective) and sHE outcomes between IBGMD and CBGMD was developed, and 
budget impact and cost-effectiveness calculations were performed, reflecting the 
US insulin-treated diabetic population. Results: On an overall population level, 
in the base-case scenario (sHE incidence 8.99%, PAT compliance 90%), usage of the 
IBGMD could lead to an extra 92,181 avoided sHEs annually, compared to a CBGMD. 
Assuming price parity of test strips across both devices ($0.21/strip at Medicare 
price $10.40 per 50-unit pack), its implementation is cost-neutral. At an average 
treatment cost of $7,598 per single sHE, this would lead to overall net cost savings 
of over $700 million per year. In alternative scenarios, achievable savings range 
from $103.7 million to nearly $6.7 billion per year. In terms of incremental cost-
effectiveness, IBGMD is considered dominant, as it features higher effectiveness 
(extra sHEs avoided) at lower overall costs compared to a CBGMD. ConClusions: 
An innovative blood glucose measurement device with pattern alert technology 
can avoid a sizeable number of sHEs and may lead to considerable cost savings, if 
implemented widely in the target population.
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objeCtives: Intra-articular injection of hyaluronic acid (HA) for knee osteoarthritis 
(OA) effectively reduces pain and delays total knee replacement (TKR) surgery; how-
ever, little is known about relative differences in clinical and cost outcomes among 
different HA products. We aimed to compare disease-specific costs and risk of TKR 
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as lower amputation rates (BLCC: -27.6% p= 0.04, HFDS: -22.2% p= 0.19) during the 
18-month follow-up period. While BLCC and HFDS patients did have higher costs 
for outpatient services (BLCC: +$7,100 p< 0.01, HFDS: +$11,947 p< 0.01), overall, these 
patients had lower average per-patient healthcare costs during the 18-month follow-
up period compared with their respective matched CC counterparts (BLCC: -$5,253 
p= 0.49, HFDS: -$6,991 p= 0.84). ConClusions: These findings suggest that use of 
BLCC and HFDS for treatment of DFU may lower overall medical costs through 
reduced utilization of costly healthcare services.
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objeCtives: In the recent Pathway CH-1 study, on-demand stimulation of the sphe-
nopalatine ganglion (SPG) by means of an implantable neurostimulation system was 
proven to be a safe and effective therapy for the treatment of chronic cluster head-
ache. Our objective was to assess the cost-effectiveness of SPG stimulation in the 
German healthcare system when compared to medical management. Methods: 
Clinical data from the Pathway CH-1 study were used as input for a model-based 
projection of the cost-effectiveness of SPG stimulation through 5 years. Medical 
management as the comparator treatment was modeled on the basis of clinical 
events observed during the baseline period of CH-1. The costs of treatment were 
derived from a previously published cluster headache costing study and2014 medi-
cation, neurostimulator, and procedure costs. We computed the 5-year incremental 
cost-effectiveness ratio (ICER) in euros per quality-adjusted life year (QALY), with 
costs and effects discounted at 3% per year. Results: SPG stimulation was pro-
jected to add 0.325 QALYs over the study period, while adding € 681 in cost, resulting 
in a 5-year ICER of € 2,097 per QALY gained. Longer follow-up periods, higher baseline 
attack frequency, and higher utilization of attack-aborting medications led to overall 
cost savings. SPG stimulation was found either cost-effective or cost-saving across 
all scenarios investigated in sensitivity analyses. ConClusions: Our model-based 
analysis suggests that SPG stimulation for the treatment of chronic cluster head-
ache, under the assumption of sustained therapy effectiveness, leads to meaningful 
gains in health-related quality of life and is a cost-effective treatment strategy in 
the German healthcare system.
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objeCtives: The objective was to study the economic and humanistic outcomes 
among acute coronary syndrome patients receiving percutaneous coronary inter-
vention (PCI) in a tertiary care setup in South India. Methods: Total 240 acute 
coronary syndrome patients visiting to tertiary care multispecialty hospital in south 
India were included in to the study from 2011 to 2013. Prior ethical approval was 
taken and patients were included after signing the consent form. All the patients 
included were receiving PCI first time. Socio-demographic, clinical diagnostic and 
risk factor data was collected using a pilot tested data collection sheet. EQ5D was 
used to collect the humanistic data on discharge, 1 month, 3 month, 6 month follow 
up. The cost incurred in the intervention and other direct costs were taken from the 
bill paid by the patient at discharge. SPSS 15.0 was used to analyse the collected data 
and demographic results were represented with descriptive statistics and Mann-
Whitney test was carried to compare the costs among both the groups. Repeated 
measures ANOVA was done to check the difference in VAS score in baseline and 
follow-up cases. Results: 80 percent of the patients were males and their mean 
age was 57.65 ±10.103 with 70 of them coming from rural background. Average 
monthly income of the patients receiving BMS and DES was found to be 10212.5 ± 
8750 and 12859.28 ± 7673.277 respectively. Almost half of the patients were having 
hypertension as a major co-morbid condition. Smoking, sedentary lifestyle and 
alcohol consumption ware predominant risk factors. Baseline EQ5D VAS scores were 
0.5054 ± 0.1848 and 0.4715 ± 0.1615 among patients receiving BMS and DES. There 
was a significant difference (p< 0.001) in the cost among the patients receiving both 
BMS and DES. ConClusions: There is a significant difference in the cost incurred 
and health related quality of life achieved among both groups due to disparity in 
economic status.
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objeCtives: To develop a system dynamics model with a stochastic component to 
analyse the cost-effectiveness of bacterial whole-genome sequencing (WGS) versus 
current typing methods to detect and monitor outbreaks of methicillin-resistant 
Staphylococcus aureus (MRSA) in the UK National Health Service (NHS). Methods: 
The model, developed in R, simulated a low-risk ward and a high-risk ward (e.g. an 
intensive care unit). Patients were assumed to move between three states: suscep-
tible, colonised, or infected (symptomatic). Healthcare workers were either uncon-
taminated or MRSA-colonised. Clinical inputs were identified from peer-reviewed 
primary research papers, systematic reviews, published models, data published 
by the NHS and from clinical experts. Relevant costs were identified from the 
Department of Health guidelines on MRSA infection management, and other pub-
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objeCtives: Estimate the economic impact derived from the use of antibiotic-
impregnated catheters vs. traditional, non-antibiotic-impregnated catheters for 
the treatment of hydrocephalus in pediatric patients with external shunts from 
a Mexican public hospital perspective (IMSS). Methods: An Excel-based deci-
sion tree was used to estimate the economic consequences of using an antibiotic-
impregnated catheter (treatment group) vs. a catheter without antibiotic (control 
group) for target population. Given procedure volume variability in comparable 
hospitals, base-case scenario assumed 100 pediatric patients with hydrocepha-
lus and only one potential infection after first catheter placement; the antibiotic-
impregnated device was assumed as second-line treatment for both groups. 
Infection rates after catheter placement for considered alternatives were taken 
from published international meta-analyses (2.4% vs. 8.7% for treatment and control 
groups, respectively). Unitary costs were provided by internal resources (antibiotic-
impregnated device) and by public bid results for base-case hospital (traditional 
catheter). Considered time horizon was < 1 year, thus no annual discount rate for 
costs was necessary. Inflation-adjusted DRGs from IMSS´s high specialty hospitals 
were used as hospitalization (catheter placement) and catheter replacement costs. 
Results are shown in 2015-adjusted USD. Due to low reinfection rates documented 
in literature, posterior infections and mortality were not considered. Results: 
The total cost of the catheter with antibiotic strategy resulted in $1,610,600, while 
the non-antibiotic catheter strategy in $1,542,200, resulting in additional $684 per 
patient treated with the antibiotic-impregnated device and $11,400 per avoided 
infection. ConClusions: The use of antibiotic-impregnated catheters appears to 
be a cost-effective alternative to treat hydrocephalus in pediatric patients in the 
Mexican setting. Local high-specialty hospitals should consider the adoption of this 
alternative as it yields less infections in target population.
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objeCtives: Deep brain stimulation (DBS), which uses an implantable device 
to modulate brain activity, has been shown to be clinically superior to medical 
therapy for treating advanced Parkinson’s disease. Our objective was to study the 
cost-utility of DBS in conjunction with medical therapy compared to best medical 
therapy (BMT) alone, using the latest clinical and cost data for the U.S. healthcare 
system. Methods: We used a decision-analytic state-transition (Markov) model 
to project Parkinson’s disease progression and associated costs for the two treat-
ment strategies. We estimated the discounted incremental cost-effectiveness ratio 
(ICER) in U.S. dollars per quality-adjusted life-year (QALY) from the Medicare payer 
perspective, considering a 10-year horizon. We evaluated the robustness of our 
projections through extensive deterministic sensitivity analyses. Results: Over 10 
years, DBS treatment led to discounted total costs of $129,345 compared to $91,026 
for BMT and added 1.69 QALYs more than BMT, resulting in an ICER of $22,713 per 
QALY. This ICER was relatively insensitive to variations in input parameters, with 
neurostimulator replacement timepoint, costs related to DBS implantation, and 
costs related to the treatment of disease-related falls having the greatest effects 
on the ratio. Across all investigated scenarios, including a 5-year horizon, ICERs 
remained under $50,000 per QALY. Longer follow-up periods and younger treatment 
age were associated with greater cost-effectiveness. ConClusions: Our findings 
suggest that DBS is a cost-effective treatment strategy in the U.S. healthcare sys-
tem across a wide range of assumptions. DBS yields substantial improvements in 
health-related quality of life at a value profile that compares favorably to other 
well-accepted therapies.
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objeCtives: To compare the real-world medical services utilization and associ-
ated costs of Medicare patients with diabetic foot ulcers (DFU) treated with either 
of the following two types of skin substitutes: bilayered living cellular construct 
(BLCC) or human fibroblast-derived dermal substitute (HFDS) with those receiving 
conventional care (CC). Methods: DFU patients were selected from Medicare de-
identified administrative claims using ICD-9-CM codes. The analysis followed an 
“intent-to-treat” design, with cohorts assigned based on use of (1) BLCC, (2) HFDS, or 
(3) CC (i.e., ≥ 1 claim for a DFU-related treatment procedure or podiatrist visit and no 
evidence of skin substitute use) for treatment of DFU in 2006-2012. Propensity score 
models were used to separately match BLCC and HFDS patients to CC patients with 
similar baseline demographics, wound severity, and physician experience measures. 
Medical resource use, lower-limb amputation rates, and total healthcare costs (2012 
USD; from payer perspective) during the 18 months following treatment initiation 
were compared separately among the two resulting matched samples. Results: 
Data for 502 matched BLCC-CC patient pairs and 222 matched HFDS-CC patient 
pairs were analyzed. Relative to matched CC patients, BLCC and HFDS patients 
had fewer days hospitalized (BLCC: -33.3% p< 0.01, HFDS: -42.4% p< 0.01) and fewer 
emergency department visits (BLCC: -32.3% p< 0.01, HFDS: -25.7% p< 0.01), as well 
